Rockwell Medical
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1995-01-01
- Employees
- 237
- Market Cap
- $95.2M
- Website
- http://www.rockwellmed.com
- Introduction
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.
Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Rockwell Medical Technologies, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02636049
- Locations
- 🇺🇸
Jasper Clinic, Kalamazoo, Michigan, United States
Triferic Pediatric Pharmacokinetic Protocol
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Rockwell Medical Technologies, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02595437
- Locations
- 🇺🇸
Lucile Packard Childrens Hospital, Stanford, California, United States
🇺🇸Nemours/A. I. DuPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.
- Conditions
- Interventions
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Rockwell Medical Technologies, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01920854
Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
- Conditions
- Interventions
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Rockwell Medical Technologies, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01894906
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2012-01-02
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- Rockwell Medical Technologies, Inc.
- Target Recruit Count
- 718
- Registration Number
- NCT01503021
- Locations
- 🇺🇸
Research Across America, Houston, Texas, United States
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
- Conditions
- Interventions
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Rockwell Medical Technologies, Inc.
- Target Recruit Count
- 294
- Registration Number
- NCT01322347
- Locations
- 🇨🇦
Investogator, Edmonton, Alberta, Canada
🇨🇦Investigator, Greenfield Park, Quebec, Canada
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Rockwell Medical Technologies, Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT01320202
- Locations
- 🇺🇸
Investigative Site, Houston, Texas, United States
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Rockwell Medical Technologies, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT01286012
- Locations
- 🇵🇷
Investigator, Fajardo, Puerto Rico
Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Rockwell Medical Technologies, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT00548249
- Locations
- 🇺🇸
Investigator, Seattle, Washington, United States
🇨🇦Investigative Site, Edmonton, Alberta, Canada